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Serotonin exerts its effects through a group of receptors in the central nervous system. 
Among these, 5-HTia remains one of the most studied of the serotonin receptors, and is 
implicated in several neuropathologies. Although the 5-HTia receptor has been extensively 
characterized in several mammalian species, it has yet to be characterized in the rabbit. This 
study was undertaken to characterize the 5-HTia receptor in rabbit cerebral cortex in terms 
of ligand binding and G protein linkage. The 5-HTia binding site in rabbit cerebral cortex 
exhibits similar characteristics to 5-HTia receptors found in other mammalian species, 
including the rat and human. Based on the results, the physiology and pathology of the 5- 
HT1A receptor can be studied confidently in the rabbit brain.
Several techniques used to investigate receptor-ligand interactions require purified 
receptor. Therefore, studies were conducted to investigate if cloned human 5 -H T ia  receptor 
expressed in Chinese Hamster Ovary (CHO) cells maintains the characteristics of 
membrane bound receptor after solubilization. Solubilized human 5 -H T ia receptor appears 
to exhibit similar characteristics in comparison to membrane bound receptor.
Parthenolide is believed to be the active constituent in feverfew, a plant that has been used 
as a folklore remedy for migraine. This substance has yet to be screened at the serotonin 
receptors which have been implicated in migraine pharmacotherapy (5-HTia, 5-HT|d and 5- 
HT2). Therefore, the interactions of this substance at these receptors was investigated. 
Parthenolide showed no activity at the 5-HTia and 5-HTid receptors. Binding was exhibited 
at 5 -HT2 receptors, but with low affinity. Parthenolide does not appear to exhibit its reputed 
effects by binding directly to serotonin receptors in the brain. It may produce its effects by 
another mechanism. Also, another constituent in the feverfew plant, or parthenolide in 
combination with other consituents, may be responsible for the plants anti-migraine effects.
u
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INTRODUCTION
I. SEROTONIN
Since the mid-nineteenth century, researchers had been aware of a substance found 
in serum that caused contractions of smooth muscle organs. In 1948, Rapport, Green, and 
Page at the Cleveland Clinic, succeeded in isolating and characterizing this serum tonic 
factor that was released from platelets during clotting of blood (Rapport, et.al., 1948). They 
appropriately named this substance "serotonin". Meanwhile, in Italy, Vittorio Erspamer was 
characterizing a substance that was found in high concentrations in the chromaffin cells of 
the intestinal mucosa (as reviewed by Erspamer, 1966). This substance also caused 
contraction of smooth muscles, and it was named "enteramine". Both substances were 
eventually purified and crystallized and in 1952, were shown to be the same chemical, 5- 
hydroxytryptamine (5-HT). After the isolation and synthesis of serotonin, interest was 
gained in examining other tissues of the body to see if this substance was present in 
structures other than blood platelets and the intestine. This led to the discovery by Twarog 
and Page in 1953 that serotonin was found in relatively large amounts in the brain (Twarog 
and Page, 1953).
With the discovery of 5-HT in the central nervous system, theories arose that various 
forms of mental illness could be attributed to abnormalities in its synthesis. This awareness 
was heightened by the observation that the tranquilizing substance, reserpine, depleted 5-HT 
(Pletscher,et.al., 1955), and that throughout the depletion a distinct behavioral depression
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
was observed. Further strengthening these behefs was the observation that the potent 
hallucinogenic substance, lysergic acid diethylamide (LSD), resembled 5-HT structurally, 
and acted as a 5-HT antagonist on smooth muscle preparations (Gaddum and 
Hameed,1954).
These beliefs held true and 5-HT is arguably the neurotransmitter which is most 
intricately involved with modem neuropsychopharmacology. 5-HT has been found to play 
an important, but not an exclusive, role in several neuropathological syndromes. The 
correlation between behavioral depression and decreased 5-HT activity has been 
established. The fact that tricyclic antidepressants and other novel antidepressants inhibit 
the re-uptake of 5-HT adds support to this hypothesis (Peroutka, et.al., 1989;van 
Zweiten,et.al. 1990). There is evidence that 5-HT plays a significant role in changes in core 
behaviors that are associated with depression. These behaviors include sleep, appetite, body 
temperature, motor activity, cognitive functions and sexual behavior (Meltzer, 1990). 
Abnormalities in 5-HT are also implicated in anxiety (Carli, et al., 1989; Peroutka, et.al., 
1989) and panic disorder (Lesch et.al., 1992). 5-HT has also been shown to play an 
important role in the pathology of migraine headache. Several pharmaceutical agents have 
been used in treating this latter ailment. All anti-migraine drugs, with the exception of 
aspirin and related compounds, appear to have important direct, or indirect, effects on the 5- 
HT receptor system (Peroutka, 1990b; Raskin, 1990).
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n . 5-HT RECEPTORS
In 1957, Gaddum and Picarelli demonstrated that there were two types of receptors 
for 5-HT in the guinea-pig ileum (Gaddum and Picarelli, 1957). They classified these 
receptors as M receptors, which could be blocked with morphine, and D receptors, which 
could be blocked with dibenzyline. A little over two decades later, Peroutka and Snyder 
demonstrated that [^H]Lysergic acid diethylamide (LSD) labeled two distinct binding sites 
in rat frontal cortex (Peroutka and Snyder, 1979). They classified these receptors as 5-HT] 
and 5 -HT2. 5-HT] receptors had high affinity for 5-HT itself and corresponded to sites 
labeled by [^H]5-HT. The 5-HT2 receptors corresponded to sites labeled by [^H]spiperone 
and had a much lower affinity for 5-HT. It was later found that the 5-HT] and 5 -HT2 
receptors subtypes did not correspond to the M and D receptors that were defined in the 
guinea-pig ileum. Subsequently, the 5 -HT3 receptor was described in the periphery, and 
potent, radiolabeled 5 -HT3 antagonists were developed using peripheral tissue models 
(Brittain et al., 1987; Fozard, 1984; Richardson et.al., 1985). The 5-HT3 receptor was then 
described in the brain (Kilpatrick, et al., 1987), demonstrating that there were more than just 
two types of receptors for 5-HT in this tissue.
These findings ushered in the modem era of the study of 5-HT receptors in the 
central nervous system. During the past couple of decades, several subtypes or "families" of 
5-HT receptors have been identified on the basis of molecular biological, pharmacological 
and biochemical properties (Peroutka, et.al.,1990). Now, much with the aid of molecular 
biology (Julius, 1991), seven major subtypes of receptors for 5-HT are understood and sor
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5-HT
Fig. 1. Schematic Representation of the Current Classification of 5-HT Receptors.
of these subtypes are further divided (Hoyer, et al., 1994; 2jfa and Pillion, 1992). Figure 1 
represents a schematic breakdown of the current classification of the 5-HT receptors.
5-HT receptors are not only divided by molecular genetics and binding specificities, 
but also by signal transduction processes which link binding events to effector 
consequences (Hoyer, et.al., 1994, Zifa and Pillion, 1992). Figure 2 represents an example 
of a membrane bound receptor coupled to an effector system. With the probable exception 
of the 5 -HT3 receptor, which is an ion channel (Maricq, et.al., 1991), the remaining 5-HT 
receptor subtypes are members of the superfamily of seven transmembrane (Figure 3), G 
protein coupled receptors (Strader, et.al., 1994).
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Fig. 2. Membrane bound receptor is activated by hormone (or drug) which 
initiates effector consequences eventually leading to a physiological response. 
This diagram shows an example of a receptor which is coupled to adenylate 
cyclase and leads to an increase in cAMP formation, (from Stryer, 1988).
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Fig.3. Representation of the structure of a 7 transmembrane receptor. All 5-HT 
receptors, with the exception of S-HTj, are considered members of this 
superfamily of G protein coupled receptors, (from Katzung, 1995).
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Guanine nucleotide binding regulatory proteins (G proteins) are proteins which bind 
to Guanosine triphosphate (GTP), thus transmitting receptor binding signals to effectors and 
second messenger systems. Figure 4 represents signal transduction through G protein 
systems. Although different effector systems have been described for 5-HT, receptors 
(Hoyer, et al., 1994; Raymond, et al., 1993), they have generally been described as being 
negatively coupled to adenylate cyclase and therefore, decrease cAMP formation. 5 -HT2 
receptors have been generally thought to be positively coupled to phospholipase C, thus 
leading to an increase in inositol triphosphate production. 5-HT4, S-HTg, and 5-HT? 
receptors have been found to be positively coupled to adenylate cyclase and lead to an 
increase in cAMP production. The effector and second messenger systems associated with 
the 5 -HT5 receptor are not currently understood. Table 1 lists aU of the currently known 5- 
HT receptors and the effector and second messenger systems that are associated with them, 
as well as radiolabeled ligands currently used to identify the receptors. Regardless of the 
effector and second messenger systems involved, G proteins mediate receptor coupling 
(Hoyer, et al., 1994).
in . 5-HTia RECEPTORS
A. Identity
The early 1980's saw the further subdivision of the 5-HT, receptor (Fozard, 1987). 
Of these, 5-HT,a represents one of the best studied of the 5-HT receptors (Fargin, et al,.
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Fig 4. Signal Transduction through G protein systems. Examples at each step are indicated 
in parentheses. G proteins that stimulate adenylate cyclase (Gs), inhibit adenylate cyclase 
(Gi), activate potassium channels (Gk), and that stimulate phopholipase C (Gp) are listed as 
examples, (from De Vivo and Maayani, 1989).
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Serotonin Receptor Radiolabeled
Ligands
Initial Result of 
Receptor Activation
Second M essenger 
Affected
5-H T ia
5-HTiB
[^H]8-OH-DPAT 
[*^^I]GTI, [^H]5-HT
Inhibition of adenylate 
cyclase
\|/ Cyclic AMP
5-HTiOa
5-HTiDg
[*“ l]GTI, [% 5-C T
5-H T ie [^H]5-HT
5-H T if [*^I]LSD
5 -HT2A [^HJketanserin,
[^Hjspiperone
Phospholipase C 
activation
Diacylglycerol and 
IP3
5 -HT2B [^H]5-HT, [̂ “ UDOI
5 -HT2C r^Hlmesulergine
5 -HT3 [^H]zacopride Opening of ion 
channel
Calcium
5 -HT4 [^H]GR113808,
[^H]SB207710
Stimulation of 
adenylate cyclase
T" Cyclic AMP
5 -HT5A
5 -HT5B
[^H]5-HT,[^^^I]LSD
pH]5-HT,[^^^I]LSD
??? ???
5-HT6 [^H]5-HT,t^^^I]LSD Stimulation of 
adenylate cyclase
^  Cyclic AMP
5 -HT7 [^H]5-HT,[*^^I]LSD Stimulation of 
adenylate cyclase
^  CycUc AMP
TABLE 1. CLASSIFICATION OF 5-HT RECEPTORS. * It should be noted that 
the 5-H T ie. 5-H T if, S-HTsa, S-HTsb, S-HTe and S-HT? receptors were characterized 
predominately by molecular biological criteria. Also, [^H]5-HT labels all 5-HTi sites 
and can only be used in combination with adequate masking ligands.
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1988; Hoyer, et al., 1994). The initial heterogeniety of 5-HTi receptors was described 
relative to the drug spiperone (Schnellman, et al., 1984). 5-HTia sites have relatively high 
affinity for spiperone, while 5-HTib sites show a much lower affinity. These two types of 
[^H]5-HT binding sites were originally defined on the basis of their affinities for unlabeled 
spiperone, and should not be confused with the 5-HT2 site, which is defined by high affinity 
binding of [^H]spiperone or [^H]ketanserin. Table 1 lists radioligands that are now used to 
characterize these receptors, as well as other 5-HT receptors.
5-HTia sites are further defined by their high affinity for aminotetralins, of which 8- 
hydroxy-2-(di-n-propylammo)-tetralin (8-OH-DPAT) is the best known. Additionally, 5- 
HT ia sites show high affinity for 5-carboxamidotiyptamine (5-CT), 5-
methoxydimethyltryptamine, ipsapirone, and buspirone (Peroutka, 1988). The 
pharmacological typing of this site has been further strengthened by the molecular cloning 
of a receptor from rat (Albert, et al., 1990) and human (Kobilka, et al., 1987; Fargin, et al.,
1988). When this cloned receptor is expressed in cell cultures, it demonstrates the 
pharmacological profile as described above, and lacks specific binding characteristics of 
other 5-HTi receptors. These binding characteristics, in association with properties of tissue 
localization and signal transduction, leads to the conclusion that a unique 5-HTia receptor is 
present physiologically (Peroutka, 1988).
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B. Clinical Implications
From a clinical perspective, the 5-HTia receptor is specifically implicated in several 
neuropathological phenomena, and therefore represents a potential target for pharmaceutical 
intervention.
The finding that buspirone is a non-benzodiazepine anxiolytic drug (Goa and Ward,
1986) and the fact that this drug has a high affinity for the 5-HT ia receptor (Traber and 
Glaser, 1987) stimulated interest in the involvement of this receptor with anxiety. Clinical 
development of selective 5-HT i a agents as potential anxiolytics is currently ongoing 
(Ablinsson, et al., 1994, Peroutka. et al., 1989). 5-H T ia receptor dysftinction has been 
linked to the pathophysiology of panic disorder as well. 5-HT ia agonists, such as 
ipsapirone, have shown considerable potential in treating this disorder (Lesch, et al., 1992),
The 5-HTiA receptor has also been implicated in behavioral depression. 8-OH- 
DPAT, a highly selective agonist at 5-HTia receptors, has demonstrated anti-depressant 
activity in certain animal models of depression (Cervo and Samain, 1987; Kennett, et al.,
1987). Further, the novel anti-depressant, cericlamine, has been shown to desensitize 
presynaptic 5-HTia autoreceptors (Jolas, et al., 1994). This leads to an increase in 5-HT 
neurotransmission, an analogous mechanism to that of tricyclic antidepressants, which 
block the reuptake of 5-HT, thus increasing the amount of 5-HT at neuronal synapses.
The 5-HTiA receptor has also gained interest in its possible involvement in migraine 
headache. Dihydroergotamine, which has long been used for the treatment of acute migraine 
attacks, has been shown to be a potent agonist at 5-H T ia receptors (McCarthy and Peroutka,
1989).
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c. Anatomical Localization
The 5-HTia receptor has been identified in several mammalian species 
(Schnellman, et al., 1984). The receptor has been found in high densities in the limbic 
system of mammalian species that have been investigated, including the rat and human 
(Palacios et al., 1990). It apparently exists as a post-synaptic receptor in these areas of the 
brain. It has also been found in high densities in the raphe nuclei of mammals, where it 
exists as a pre-synaptic autoreceptor (Palacios, et al., 1990).
D. Rabbit Brain 5-HTia Receptor
Although the 5-HTia receptor has been identified in the brain of the rabbit (Xiong 
and Nelson, 1989), it has never been fully characterized in terms of ligand binding and G 
protein linkage. Pre-synaptic autoreceptors in the rabbit brain are apparently not of the 5- 
HT ia type (limberger, et al., 1991; W æber and Palacios, 1992). The type of receptor that 
was identified by Xiong and Nelson (1989) is the post-synaptic 5-HTia receptor. The rabbit 
is used extensively in biomedical research, especially in cardiovascular and 
pharmacological studies (Benedini, et al., 1995.; Ferrari, et al., 1991; Leff and Martin, 1988; 
Woodley and Barclay, 1994). In particular, the rabbit is often used when investigating 5-HT 
receptors in the brain (Dewar, et al., 1990; Feuerstein, et al., 1987; Schoups, et al., 1986; 
Schoups and DePotter, 1988).
The complete characterization of the 5-HT ia receptor in rabbit brain will allow for 
an even greater understanding of the receptor across mammalian species. There is a high
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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amount of applicability to humans when similar results are seen across different species, 
especially those from various orders. Therefore, the study of 5-HTia receptor physiology 
and pathology could be confidently studied in the rabbit brain.
E. 5 -H T ia  Characterization
A number of drugs have been shown to be useful in the characterization of 5-HTia 
receptors. A brief description of some of these drugs and their utility in this study foUows;
8-OH-DPAT The aminotetralin, 8-OH-DPAT, was discovered in the early 1980's 
(Zifa and Pillion, 1992) and its discovery was soon followed by the development of the 
tritiated compound (Gozlan et al., 1983). It was found to be a highly selective, full agonist at 
the 5-HTiA receptor, allowing for more detailed study of this specific receptor subtype. 
Other radioligands have been described for 5-HTia, but none have been able to surpass 
[^H]8-OH-DPAT in its overall usefulness (Hoyer, et al., 1994).
Buspirone As previously described, the fact that buspirone is a non-benzodiazepine 
anxiolytic drug (Goa and Ward, 1986), and the finding that it has high affinity for the 5- 
HT ia receptor (Traber and Glaser, 1987), sparked interest in the involvement of this 
receptor with anxiety. Buspirone is described as a partial agonist at 5-HT,A receptors, 
meaning that it fully occupies these receptors, but produces less than the maximal response
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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produced by a full agonist. It is often used in displacement studies of [^H]8-OH-DPAT 
when studying this receptor.
Propranolol Propranolol has been found to directly displace [^H]5-HT from its 
binding sites in rat cortex (Middlemiss, 1984) providing evidence for an interaction of this 
beta-adrenoreceptor antagonist with 5-HT receptors. The (-) stereoisomer of propranolol 
was later found to block selective 5-HT ia agonists (Sprouse and Aghajanian, 1986) and has 
therefore become useful in the characterization of this receptor as a 5-H T ia antagonist.
Spiroxatrinc The compound [^H]spiroxatrine was initially described as labeling 5- 
HTia sites in the rat hippocampus (Nelson, et al., 1987). It is a selective agonist at the 5- 
HTia receptor and continues to be utilized by researchers in the study of this receptor 
(Fargin et al., 1988; Hoyer et al., 1994).
WB 4101 [^H]2-(2,6-dimethoxyphenoxyethyl)aminomethyl-l ,4-benzodioxane 
([^H]WB 4101), like spiroxatrinc, was originally described as labeling 5-HT]A sites in the 
rat brain (Norman et al., 1985). It is a selective agonist at these receptors as well, and its use 
continues for those investigating the 5-HT]A receptor in the brain (Nelson, et al., 1987; Zifa 
and Pillion, 1992).
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Methiothepin The compound methiothepin has a high affinity for 5-HTia receptors. 
Methiothepin displays antagonist activity at 5-HTia receptors, and it is often used in 
addition to other ligands when characterizing this receptor (Gozlan, et al., 1983; Hoyer, et 
al., 1985; Zifa and Pillion, 1992).
Dopamine The naturally occuring monoamine, dopamine, has low affinity for 5- 
HTia and 5-HT receptors as a whole. However, it is often used when characterizing the 5- 
HTia receptor, mainly as a control and for comparative purposes (Fargin, et al., 1988; 
Nelson, et al., 1987; Norman, et al., 1985).
Gamma-S-GTP and Gamma-S-ATP Stable Guanosine triphosphate (GTP) 
analogues are often used to determine if a receptor is G protein-linked. Guanine nucleotides 
decrease high affinity agonist binding to receptors by converting them to a low affinity state 
(Fargin, et al., 1988). Therefore, GTP should decrease the binding of agonists, like 8-OH- 
DPAT, for 5-HT,A receptors. Adenosine triphosphate (ATP) analogues should not decrease 
high affinity binding, and are therefore used as a control when investigating G protein 
linkage of a receptor.
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IV. HUMAN 5 -H T ia  RECEPTOR
The 5-HTia receptor has been cloned from the human (Kobilka, et al., 1987, Fargin, 
et al., 1988), and this intronless gene encodes a protein which has been expressed in several 
tissue culture cell lines. The particular cell line in which the receptor is expressed can have a 
major bearing on the nature of signal transduction processes. Originally expressed in COS 
7, a monkey kidney cell line, the receptor is negatively coupled to adenylate cyclas ( Fargin, 
et al., 1989). When it is expressed in HeLa cells, it has been found to be negatively coupled 
to adenylate cyclase (Fargin, et al,, 1989), but also positively coupled to protein kinase C 
(Raymond, et al,, 1989). In fibroblast L cells, the receptor is positively coupled to 
phospholipase C (Liu, et al., 1991). When the receptor has been expressed in Chinese 
Hamster Ovary (CHO) cells, it has been found to be negatively coupled to adenylate cyclase 
(Raymond, et al., 1993), and this is the result which is most often reported from non­
transfected systems in other species (Hoyer, et al., 1994; Zafa and Fillion, 1992).
Because the human 5-HT ia receptor expressed in CHO cells shows similar 
characteristics to the receptor found in non-transfected systems in other species, it should 
serve as a valid model of comparison to the characteristics of the rabbit brain 5-H T ia 
receptor.
Some techniques that are used to create a greater understanding of the interactions 
between receptors and ligands, such as multidimensional NMR (Dratz, et al., 1993), require 
purified receptor. The goal of solubilizing 5-HT receptors is to obtain a preparation that 
retains the pharmacological and biochemical characteristics of the membrane-bound
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receptor. Binding studies and GTP inhibition studies with 5-H T ia receptor solubilized from 
CHO cells can help to achieve this goal.
V. 5-HT INVOLVEMENT IN MIGRAINE
The early 1980's saw the beginning of thoughts that 5-HT receptors may be involved 
in the pathology of migraine headache (Houston and Vanhoutte, 1986; Janssen, 1983). With 
the exception of aspirin and other non-steroidal anti-mflamrriatory drugs that have been 
used in treating this ailment, all anti-migraine drugs appear to have either a direct or indirect 
effect on the 5-HT receptor system (Peroutka, 1990b; Raskin, 1990). Ergot alkaloids are the 
class of compounds that have been used most often in treating acute migraine attacks. One 
of these substances, dihydroergotamine, is most potent as a 5-HTia agonist, but also shows 
high affinity for the 5-HTio receptor (McCarthy and Peroutka, 1989). Sumatriptan, which is 
a novel acute migraine agent, is most potent at 5-HT id receptors as an agonist, but also 
displays high affinity for 5-HTia (McCarthy and Peroutka; 1989). Therefore, agonist 
activity at 5-HTia and/or 5-HTid receptors appears to be efficacious for treating acute 
migraine attacks. Some other useful anti-migraine substances are drugs that act as 5-HT2 
antagonists. An example in this class of compounds is methysergide, and these types of 
substances have been found to be most useful in migraine prophylaxis (Peroutka, 1990b).
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VI. PARTHENOLIDE
A. Background
European feverfew, Tanacetum parthenium, is a plant that has been used as a folk 
remedy for migraine for several years (Awang, et al., 1991; Maries, et al., 1992). 
Parthenolide, one of the major compounds found in feverfew, is believed to be the active 
constituent of the plant (Awang, et al., 1991), The finding that parthenolide inhibits the 
release of 5-HT from blood platelets (Groenewegen and HepinstaU, 1990; Maries, et al., 
1992) has stimulated interest in the interactions of this substance with the serotonergic 
system. This compound has yet to be investigated at the 5-HT receptors that have been 
implicated in migraine therapy (5-HTia, 5-HTid and 5 -HT2). Analysis of the interaction of 
parthenolide with these 5-HT receptors will help lead to a greater understanding of the 
mechanism of action behind this substance.
B. Screening at 5 -H T ia , 5 -H T id  and 5 -H T 3 Receptors
After the characterization of the 5-H T ia receptor in rabbit brain, parthenolide can be 
confidently screened at this receptor using the rabbit model. The 5-H T id (Limberger, et al., 
1991) and 5-HT2 (Schoups, et al., 1986) receptors have both been characterized in the rabbit 
brain, and therefore the interaction of parthenolide with these receptors can be legitimately 
studied in this species.
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Drugs that have been used to study 5-HTia receptors have been previously 
described. The drugs that will be used to investigate the interaction of parthenolide with 5- 
HT id and S-HT; receptors in this study are briefly described below:
5-CT [^H]5-CT has been used as a selective ligand for investigating the 5-HTid 
receptor (Peroutka, 1988). However, the compound has also exhibited a high affinity for 5- 
HTia receptors. Therefore, when 5-CT is used, it is necessary to mask the 5-HTia receptors 
with a high amount of the 5-HTia selective ligand, 8-OH-DPAT.
Ketanserin [^H]Ketanserin was the first potent S-HTi antagonist identified (Leysen, 
et al., 1982) and although it binds with high affinity to all 5-HT2 receptors, it has recently 
been shown to bind most specifically to S-HTia receptors (Hoyer, et al., 1994). It has also 
been shown that [^HJketanserin displays a high affinity for binding to monoamine 
transporters (Dewar, et al., 1990; Van Wijngaarden, et al., 1990). Despite its limitations, 
and because no better selective 5 -HT2 agents are known, [^HJketanserin is still the most 
fiequently used ligand for studying these receptors (Van Wijngaarden, et al., 1990).
Methvsergide The compound methysergide, previously described as an anti- 
migraine substance, is an antagonist at 5 -HT2 receptors (Peroutka, 1990b). It has been 
frequently employed by researchers who are further characterizing 5-HT2 binding sites that 
have been labeled by [^Hjketanserin (Schoups, et al., 1986, Zifa and Pillion, 1992).
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Mesulereine [^H]Mesulergine was found to label S-HTz sites over a decade ago 
(Zifa and Pillion, 1992). lik e  methysergide, it is an antagonist at these receptors. It is also 
used frequently by researchers when investigating 5-HT2 receptors (Peroutka, et al., 1988; 
Zifa and Pillion, 1992).
v n . SPECIFIC OBJECTIVES
A. To analyze the 5-HT 1 a receptor in rabbit cerebral cortex in terms of ligand binding and G 
protein link^e .
B. To compare values obtained from the characterization of this receptor in rabbit brain 
with those from rat and human, in order to examine if this receptor exhibits similar 
characteristics across these three species.
C. To conduct preliminary binding and GTP inhibition studies of solubilized human 5-HTia 
receptor, in order to investigate if this receptor maintains the characteristics of membrane 
bound 5-HTiA receptor.
D. To investigate the interaction of the natural product parthenolide, which has been 
implicated in the treatment of migraine, with the 5-HT receptors that have gained 
recognition in treating this ailment.
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MATERIALS AND METHODS
I. CHEMICALS
Chemicals, Reagents, and Drugs were obtained from the indicated sources. 8-OH- 
DPAT, Buspirone, Methiothepin, Propranolol, Spiroxatrine, WB 4101 (Research 
Biochemicals, Inc.; Natick, MA). [^H]5-HT, [^H]8-OH-DPAT, [^H]Ketanserin, [^H]5-CT 
(New England Nuclear; Boston, MA). Guanosine 5'-0-(thiotriphosphate) (gamma-S-GTP), 
[3-[(3-Cholamidopropyl)-dimethylammonio]-l-propanesulfonate] (CHAPS), n-octyl-b-D- 
glucopyranoside. Serotonin (5-HT) (Calbiochem; LaJolla, CA). Dopamine, Parthenolide, 
Sodium cholate (Aldrich Chemical Co.; Milwaukee, WT). Ham's F-12 medium. Fetal Calf 
Serum (FCS), Earle's Balanced Salt Solution (EBSS), Geneticin (GIBCO/BRL; 
Gaithersburg, MD). Adenosine 5'-0-(thiotriphosphate) (gamma-S-ATP), Trizma base 
(Tris), Calcium chloride, Pargyline (Sigma Chemical Co.; St. Louis, MO). Tetrasodium 
ethylenediamine tetraacetic acid (EDTA), Magnesium sulfate, Ascorbate (Baker Chemical 
Co.; Phillipsburg, NJ). Chinese Hamster Ovary (CHO) Cells (a gift from Dr. John 
Raymond, Duke University).
n . MEMBRANE PREPARATION
Brains were removed from New Zealand White rabbits anesthesized with 
pentobarbital and rapidly dissected at 4°C. After dissection, brain tissue was frozen in liquid
20
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nitrogen and stored at -70® C until the day of use. Cerebral cortex prepared for assay was 
thawed in 40 volumes of ice-cold buffer (50mM Tris, pH 7.4), minced, and homogenized in 
a Polytron (setting 5 for 30 seconds). Homogenates were centrifuged at 4® C at 12,000 x g 
for 45 minutes and pellets were resuspended in an equivalent volume of buffer. This was 
followed by a second round of homogenization and centrifugation. Rat cerebral cortex was 
prepared following the same procedure.
m . 5 -H T ia  s a t u r a t i o n  b in d in g  a s s a y s
Binding assays were performed using modifications of several techniques that have 
been previously described (Fargin, et.al.,1988; Nelson, et.al.,1987; Pierce, et.al.,1989; 
Xiong, et.al., 1989). To assay for binding activity, rabbit or rat membrane pellets were 
resuspended in 60-80 volumes of Tris buffer containing lOuM pargyline and 4mM calcium 
chloride (binding buffer). A final assay volume of 1.0 ml contained 0.8 ml of homogenate,
0.1 ml of either binding buffer (representing total binding) or serotonin (10 uM final 
concentration for non-specific binding), and 0.1 ml of [^H]-8-OH-DPAT (specific activity: 
132.8 Ci/mmol) at varying concentrations. Incubations were for 20 minutes at 30® C 
followed by rapid filtration through glass fiber filters (Whatman GF/B or S & S #32) with 
three washes of ice-cold Tris buffer (14 mis total). Filters were counted in 5 mis o f Ecoscint 
scintillation fluid in a Beckman Liquid Scintillation System. Tritium was counted at 50%
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efficiency. Protein content was analyzed colorimetricaliy using the Bradford technique 
(Bradford; 1976).
IV. 5 -H T ia  DISPLACEMENT EXPERIMENTS
Displacement experiments were identical except that only 0.7 ml of homogenate 
was used and an additional 0.1 ml of displacing drug (i.e. buspirone, propranolol) at varying 
concentrations, was added making up the final assay volume of 1.0 ml. The drugs were 
dissolved at high concentration in distilled water followed by dilution to their final 
concentrations in binding buffer. As a result of this dilution technique, all drugs were 
delivered to the assay tubes at virtually identical buffer concentrations as control values. All 
of the assays were performed in duplicate or triplicate. Each of the displacing drugs was 
analyzed in at least three separate experiments in rabbit cerebral cortex with the exception 
of gamma-S-ATP, which was performed twice. The buspirone displacement experiment in 
rat cerebral cortex was performed only once.
To investigate the possible interactions of the agent used to anesthetize animals 
(pentobarbital), a single displacement experiment was conducted. The potential displacing 
agent, pentobarbital, was investigated over a 100 million fold concentration range (10 "  M 
to 10^ M) under identical conditions used in other displacement experiments.
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V. HUMAN RECEPTOR
CHO cells that have been transfected with clonal cDNA for the 5-H T ia receptor 
were grown in culture. Cells were grown in culture at 37® C in a humidified atmosphere of 
5% CO2, 95% air. Cells were cultured in monolayers in 225cm^ flasks and were nourished 
with Ham's F-12 medium fortified with 10% FCS and containing 200ug/ml of geneticin. 
Membrane preparation for binding assays was similar to that for rabbit and rat cerebral 
cortex. Cells were first washed with 10ml of 0.25% trypsin in physiological saline, and then 
harvested in an equivalent volume of trypsin. The reaction was stopped by the addition of 
lOmls of ice-cold F-12 medium containing 10% FCS. Cells were then centrifuged at 4® C at
1,000 X g for 5 min. The resulting pellet was washed with 20mls of Earle's balanced salt 
solution followed by another round of centrifugation. The pellet was resuspended in 20mls 
of CHO lysis buffer (20mM Tris, 2mM EDTA, pH 7.4) and homogenized in a Dounce glass 
homogenizer. The homogenate was centrifuged at 4® C at 12,000 x g for 45 min. The pellet 
was resuspended in an equivalent amount of lysis buffer and was followed by another round 
of homogenization and centrifugation. Final membrane pellets were resuspended in 20- 
25mls of 5-H T ia binding buffer. Incubations involving CHO cells were at 30° C, for 30 
min. All dose-response and displacement assays were performed as previously described for 
rabbit cerebral cortex.
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VI. SOLUBILIZED HUMAN RECEPTOR
CHO Cells were harvested in the same manner as previously described for human 
receptor. Following the final wash, 1ml of solublizing solution containing either CHAPS, 
Na cholate, or n-octyl-b-D-glucopyranoside (0.6%) was added to the membrane pellet 
which was allowed to sit on ice for 1 hour. The pellet was then centrifuged at 4® C at 12,000 
X g for ISmin. The final supernatant was resuspended in 20mls of binding buffer.
v n . PARTHENOLIDE
Because of the non polar nature of parthenolide, it was necessary to first dissolve 
the chemical in absolute ethanol before diluting it in binding buffer. Displacement studies at 
the 5-HTia receptor were performed in the same manner as previously described. 
Displacement studies investigating the S-HTz receptor used [^H]ketanserin (specific 
activity: 60 Ci/mmol) as the radiolabeled ligand which has been shown to bind with high 
affinity to these receptors (Hoyer et.al.; 1994). Non-specific binding was determined in the 
presence of lOuM mesulergine in these assays. Displacement assays investigating binding at 
the 5-HTid receptor used [^H]5-CT (specific activity: 15 Ci/mmol) as the radiolabeled 
ligand. Because [^H]5-CT also shows high affinity for 5-HTia receptors (Hoyer et.al.; 
1994), 8-OH-DPAT was used at a concentration of 0.1 uM to mask these binding sites. To 
determine whether parthenolide displaces serotonin from any high affinity sites.
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Liquid Scintillation System.
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studies using rapid 
filtration.
Fig. 5. Flowchart of experimental protocol.
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displacement assays utilizing [^H]-5-HT (specific activity: 15 Ci/mmol) were also 
conducted. Non-specific binding was determined in the presence of lOuM 5-HT when 
[^H]5-CT and [^H]5-HT were used as the radiolabeled ligands. An experiment was also 
conducted to investigate the potential interaction of extracts of feverfew with [^HJketanserin 
binding. A liquid extract containing 95% ethanol was tested, as well as crude extracts that 
were reconstituted in pure ethanol.
Vra. STATISTICS
Binding parameters were analyzed by computerized procedures (PC NON-UN; 
minitab) as well as fitted by hand. K4 values were determined from IC50 values as described 
by Cheng and Pmsoff (1973).
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RESULTS
I. 5-HT ia s a t u r a t i o n  BINDING
[^H]8-OH-DPAT, a selective 5-HTia agonist, showed high affinity binding to rabbit 
cerebral cortex membranes. Figure 6 shows a representative dose-response experiment in 
which points were generated in triplicate. When non-specific binding (in the presence of 
lOuM 5-HT) was subtracted from total binding, a specific, saturable binding process is 
observed. Using Scatchard analysis of specific binding (Figure 7), an apparent Ka of 1.1 +/- 
0.3nM with a Bmax of 480 +/- 130 fmols/mg protein was obtained (average of 3 
experiments; total dose range tested was 0.125nM-5.0nM). Scatchard plots were linear, and 
Hill plots of the transformed specific binding data (Figure 8) generated a Hill coefficient of 
0.96 +/- 0.01, which suggests a single class of non-interacting binding sites. A longer time 
frame of incubation (30 min) was also investigated, and saturation binding was found to be 
no better than with a 20 min incubation time. Also, homogenates that were prepared from 
fresh brain tissue, and then frozen at -80® C, show markedly lower binding activity when 
they are later tested. Based on these results, and those reported in the literature, the 
conditions are optimal. [^H]8-OH-DPAT also showed high affinity binding to rat cerebral 
cortex membranes. Scatchard analysis of specific binding yielded an apparent Kd of 0.8nM 
in the rat brain (Table 3).
27
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n . 5-h t ia  d is p l a c e m e n t  e x p e r im e n t s
Figure 9 represents displacement curves in which drugs of known pharmacological 
specificity competed for binding with [^H]8-OH-DPAT. Drugs with high (spiroxatrine), 
medium (propranolol) and low (dopamine) affinity for 5-HT i a receptors are shown. Kj's for 
all displacing drugs that were tested are summarized in Table 2. The buspirone 
displacement experiment that was conducted in rat cerebral cortex yielded a K, value of 37 
+/- 12 nM (Table 3).
The inhibitory effects of the gamma S analogues of GTP and ATP are summarized 
in Figure 10. GTP dose-dependently inhibited the binding of specific [^H]8-OH-DPAT to 
rabbit cerebral cortex membranes. The IC50 value for the GTP interaction is 0.3uM. 
Gamma-S-ATP was essentially without activity.
Maximum displacement achieved with pentobarbital was 70% at a concentration of
1.0 mM. An apparent IQ of 3.0 uM was determined. In a rough calculation using an estimate 
of the pentobarbital concentration present at anesthesia, the final pentobarbital concentration 
present in assay tubes following tissue preparation would be less than one-ten thousandth of 
the pentobarbital IQ. It was estimated that this concentration would affect experimental 
values for other dmgs by less than 5%.
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Fig.6. Concentration-dependent binding of [^H] 8-OH-DPAT to membranes from 
rabbit cerebral cortex. Results are from a representative experiment in which 
points were generated in triplicate (data shown are mean ± S.E.M.). Specific 
binding (□ ) was derived by subtracting non-specific binding (■) from total 
binding (A).
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Fig. 7. Scatchard analysis of the binding of [^H] 8-OH-DPAT to 5-HT,A receptors in 
rabbit cerebral cortex. Results are from a representative experiment in which points 
were generated in triplicate.
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Fia. 8. Hill plot of transformed specific binding data of [^H] 8-OH-DPAT to rabbit 
cerbral cortex membranes. Results are from a representative experiment in which 
points were generated in triplicate. [L] represents free ligand. [LR] represents bound 
ligand. Z= [LR]max-[LR].
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Fig. 9. Displacement of specific [^H] 8-OH-DPAT binding from rabbit cerebral cortex 
membranes. [^H] 8-OH-DPAT concentration was O.SnM. Points are mean ± S.E.M. 
Displacing drugs: spiroxatrine (A); propranolol (□); dopamine (■).
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Table 2 Affinities o f ligands for [^H] 8-OH-DPAT binding sites
COMPOUND K i ( n M )
Spiroxatrine 2.4 ± 0.7
W B4101 3.0 ± 0.7
Buspirone 26 ± 9
Propranolol 78 ± 2
Methiothepin 807 ± 93
Dopamine 7790 ± 38
Values represent the mean ± S.E.M. for three separate experiments performed in 
duplicate or triplicate. Experimental conditions and calculations were described in 
Methods.
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Fis. 10. Concentration-dependent inhibitory effect of gamma S GTP and gamma S 
ATP for [^H] 8-OH-DPAT binding to rabbit cerebral cortex membranes. Gamma S 
GTP (A), points are mean ± S.E.M. for three experiments. Gamma S ATP (□), 
points are mean values from two experiments.
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n i .  HUMAN RECEPTOR
[^H]8-OH-DPAT showed high affinity binding to human 5-H T ia receptor expressed 
in cultured CHO cells. Figure 11 represents a dose-response experiment in which points 
were generated in triplicate. Using Scatchard analysis of specific binding, an apparent Ka of 
0.6nM with a B^ax of 770 fmoles/mg protein was obtained (Figure 12). A Hill plot of the 
transformed specific binding data generated a Hill coefficient of 0.95 (Figure 13), 
suggesting a non-interacting binding site. Displacement studies of specific [^H]8-OH-DPAT 
binding with buspirone and propranolol generated K, values of 5.1 +/- 1.6 nM and 73 +/- 
0.2 nM, respectively (Figure 14). Table 3 shows a comparison of saturation binding and 
displacement data obtained in the rabbit, rat and human.
IV. SOLUBILIZED HUMAN RECEPTOR
Displacement curves generated by competition of buspirone with specific [^H]8- 
OH-DPAT binding at solubilized human 5-HTia receptor are shown in Figure 15. 
Displacement curves at receptors solubilized with both CHAPS and Na cholate are 
represented. Receptor solubilized with Na Cholate produced a Kj value of 4.3 +/- 0.5 tiM for 
buspirone. Receptor solubilized with CHAPS produced a Ki value of 80 +/- 10 nM. 
Experiments involving n-octyl-b-D-pyranoside (0.6%) as the solubilizing agent failed to 
generate a displacement of [^H]8-OH-DPAT by buspirone. Figure 16 shows a
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concentration-dependent inhibitory effect of the stable GTP analogue, gamma-S-GTP on 
specific [^H]8-OH-DPAT binding in human receptor solubilized with CHAPS. The IC50 
value calculated for the GTP interaction is 0.1 uM.
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Fie. 11. Concentration-dependent binding of [^H] 8-OH-DPAT to human 5-HT ia 
receptor expressed in cultured CHO cells. Results are from an experiment in which 
points were generated in triplicate. Specific binding (□ ) was derived by subtracting 
non-specific binding (■ ) from total binding (A).
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Fig. 12. Scatchard Analysis of the binding of [^H] 8-OH-DPAT to human 5-HT ia 
receptor expressed in cultured CHO cells. Results are from an experiment in which 
points were generated in triplicate.
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Fig. 13. Hill plot of transformed specific binding data of [^H] 8-OH-DPAT to 5- 
HT ia receptor expressed in cultured CHO cells. Results are from an experiment in 
which points were generated in triplicate.[L] represents free ligand. [LR] represents 
bound ligand. Z= [LR]max-[LR].
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Fig. 14. Displacement of specific [^H] 8-OH-DPAT binding from human 5-HT ia 
receptor expressed in cultured CHO cells. [^H] 8-OH-DPAT concentration was 
O.SnM. Points are mean ± S.E.M. Displacing Drugs: buspirone (□); propranolol (A).
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Table 3 Comparison of Values in Rabbit, Rat and Human
Saturation Binding TKd̂
Rabbit 1.1 ± 0.3 nM
Rat 0.8 nM
Human 0.6 nM
Disolacement fKjl
Buspirone Propranolol
Rabbit 2 6 ±  9nM 7 8 ±  2nM
Human 5.1 ± 1.6 nM 73 ± 0.2 nM
Rat 37 ±  12 nM
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Fig. 15. Displacement of specific [^H] 8-OH-DPAT binding from solubilized human 
5-HT ia receptor by buspirone. Points are mean ± S.E.M. Results represent receptor 
solubilized by CHAPS (A) and Na cholate (□ ).
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Fig. 16. Concentration-dependent inhibitory effect of gamma S GTP for [^H] 8-OH- 
DPAT binding to human 5-HTia receptor solubilized with CHAPS. Points are mean ± 
S.E.M. for two experiments.
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V. PARTHENOLDOE
Comparison of displacement of specific [^H]8-OH-DPAT from rabbit cerebral 
cortex of parthenolide with a drug of known pharmacological specificity for these receptors, 
buspirone, is shown in Figure 17. The natural product parthenolide shows very low binding 
activity at the 5-HTi a receptor, and exhibited a IQ value in excess of 1.0 mM.
Figure 18 represents a comparison of the displacement of [^H]ketanserin by 
parthenolide and a drug with known specificity at 5 -HT2 receptors, mesulergine. Non­
specific binding was determined in the presence of lOuM methysergide in these 
experiments. Mesulergine produced a K, value of 8.3 +/- 0.7 nM and parthenolide exhibited 
an IC50 value of exactly l.OmM. Figure 19 represents a comparison between parthenolide 
and another drug with known specificity for these receptors, methysergide. Non-specific 
binding was determined in the presence of lOuM mesulergine in these studies. 
Methysergide exhibited a K, value of 5.7 +/- 1.5 nM and parthenolide produced a IQ value 
of 234 +/- 94 uM. The affinities of these ligands for [^HJketanserin binding sites are 
summarized in Table 4.
The experiments involving [^H]5-CT failed to show any displacement of this ligand 
by parthenolide. Experiments with [^H]5-HT also showed no displacement from its binding 
sites by parthenolide. Crude extracts of feverfew that were reconstituted in pure ethanol did 
not displace [^H]ketanserin from its binding sites. However, the liquid extract containing 
95% ethanol displaced [^H]ketanserin by 51.3 % in comparison to control values.
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Fig. 17. Displacement of specific [^H] 8-OH-DPAT binding from rabbit cerebral 
cortex membranes. [^H] 8-OH-DPAT concentration was 0.5nM. Points are mean ± 
S.E.M. Displacing drugs: buspirone (□ ); parthenolide (A).
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Fig. 18. Displacement of specific [ H] ketanserin binding from rabbit cerebral cortex 
membranes. pH]Ketanserin concentration was 0.25nM . Displacing drugs: 
mesulergine (□ ); parthenolide (A).
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Fig. 19. Displacement of specific [^H] ketanserin binding from rabbit cerebral cortex 
membranes. [^H] Ketanserin concentration was 0.25nM. Points are mean ±  S.E.M. 
Displacing drugs: methysergide (□ ); parthenolide (A).
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Table 4 Afflninties of ligands for [^H] Ketanserin binding sites
COMPOUND Ki
Methysergide 5.7 ± 1.5 nM
Mesulergine 8.3 ± 0.7 nM
Parthenolide 234 ± 94 uM
Values represent the mean ± S.E.M. Experimental conditions and calculations were 
described in Methods.
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RABBIT BRAIN 5-HT ia RECEPTOR
The 5-HTia receptor has been identified in several mammalian species 
(Schnellman, et al., 1984). Although the 5-HTia receptor has been identified in the rabbit 
brain (Xiong and Nelson, 1989), it is surprising that the receptor has not been fully 
characterized in terms of ligand binding and G protein linkage. Based on the results reported 
here, the S-HTia receptor in rabbit brain exhibits similar characteristics in comparison to the 
5-HTia receptor that is found in other mammalian species.
8-OH-DPAT is a highly selective, full agonist at the 5-HTia receptor. To date, no 
ligand has been able to surpass the usefulness of t^H]8-OH-DPAT in identifying and 
characterizing the 5-HTia receptor (Hoyer, et al., 1994). 8-OH-DPAT showed high affinity 
binding to membranes from rabbit cerebral cortex. A specific, saturable binding process was 
observed and produced an apparent Ka value of 1.1 nM. This Kd is similar to those reported 
in other mammalian species with direct binding of 8-OH-DPAT. Reported Ka's range from 
0.4 to 3.0 nM, thus suggesting that the rabbit cerbral cortex 5-HTia binding site is a 5-HTia 
receptor similar to 5-HTia receptors in other species (Beer, et al., 1990; Hoyer, et al., 1994). 
In addition. Hill plots of the transformed specific binding data produced a Hill coefficient of
49
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0.96 +/- 0.01 , suggesting that this is a single class of non-interacting binding sites. The 
linear Scatchard plots also support this conclusion that this is a single class of binding sites.
To further characterize this receptor in rabbit cerebral cortex, a series of 
displacement experiments were conducted in which drugs with known specificity for the 5- 
HTia receptor in other species competed for binding with [^H] 8-OH-DPAT.
Spiroxatrine exhibited high affinity for the receptor with a IQ value of 2.4 nM. This 
falls within the range of 0.79 to 7.94 nM that has been reported for other species (Zifa and 
Pillion, 1992). It is very close to the IQ value of 1.8 nM that was reported by Fargin, et al. 
(1988) for the clone of the human 5-HTia receptor. WB 4101 also showed high affinity for 
the 5-HTiA receptor as has been shown by other researchers (Nelson, et al., 1987; Norman, 
et al., 1985). The IQ value of 3.0 nM reported here is very close to the value of 5.6 nM that 
was reported by Harrington, et al. (1991) in rat brain.
IQ values for buspirone at the 5-HTia receptor have been reported as ranging from 
1.2 to 29.5 nM (Zifa and Pillion, 1992). Therefore, the value of 26 nM reported here, is 
within this range. This value is very close to the 29.5 nM IQ that was reported by Gozlan, et 
al. (1983) in the rat hippocampus.
The rank order potencies of propranolol (Hoyer, et al., 1994; Sprouse and 
Aghajanian, 1986) and dopamine (Pargin, et ai., 1988; Nelson, et al., 1987) are consistent 
with 5-HTiA receptors in other mammalian species. The only result that raises questions is 
that of methiothepin, which produced a IQ of 807nM. The reported range of IQ's for this 
substance is firom 2.2 to 89.1 nM (2Lifa and Pillion). This is certainly a large range in
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comparison to some of the other ligands used in characterizing this receptor, but the result 
reported here is almost ten times that of the 89.1 nM K, reported by Gozlan, et al. (1983). 
Some of the assay conditions used in previous studies did differ from those that were used 
in these experiments. For example Norman, et al. (1985), who reported a Kj of 6.7 nM for 
methiothepin in the rat, used a 40 min incubation time at 37® C. Gozlan, et al. (1983) used 
an incubation time of only 10 min at 37® C in a 2ml final assay volume. They reported the 
Ki of 89.1 nM, yet their value for buspirone was very close to the one reported here for the 
rabbit. Although assay conditions have been shown to differ and can certainly be 
responsible for some of the differences in reported values, experimental error must be 
considered for the high K, value of methiothepin in the rabbit brain. Also, it should be 
pointed out that methiothepin is not highly specific for this receptor or any other receptor. 
Therefore, the significance of this reported difference is unclear.
Because 5-HTia receptors belong to the superfamily of 7 transmembrane G protein 
coupled receptors, it was necessary to investigate G protein linkage. Guanine nucleotides 
have been shown to decrease the affinity of agonists for their receptor (Nelson, 1989). 
Therefore, inhibition experiments utilizing the stable GTP analogue, gamma-S-GTP, were 
conducted. Gamma-S-GTP dose-dependently disrupted [^H]8-OH-DPAT binding to rabbit 
cerebral cortex membranes. The IC50 value for the reaction was 0.3 uM. As a control, the 
gamma-S analogue of ATP was also investigated for inhibitory properties. Gamma-S-ATP 
was essentially without activity. These results are consistent with a receptor which is G 
protein linked (Fargin, 1988).
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To further investigate the characteristics exhibited by the rabbit brain 5-HTia 
receptor, studies were conducted to compare binding data obtained in rabbit brain with that 
obtained from rat brain and cloned human 5-HTia receptor.
Human 5-H T ia receptor (Fargin, et al,, 1988; Kobilka, et al., 1987) was expressed in 
cultured CHO cells (a gift from Dr. John Raymond of Duke University). When the 5-H T ia 
receptor is expressed in CHO cultures, it has been found to be negatively coupled to 
adenylate cyclase (Raymond, et al., 1993). This is the second messenger system that is most 
often reported in non-transfected systems in other species. Therefore, this receptor appears 
to exhibit similar characteristics to the 5-HT ia receptors found in other mammalian species, 
and should serve as a valid model for comparison to the rabbit brain receptor.
[^H]8-OH-DPAT showed high affinity binding to the cloned human S-HTja 
receptor, and upon Scatchard analysis of specific binding, yielded an apparent Kd of 0.6 nM. 
The Hill coefficient obtained for human receptor was 0.95 suggesting a single site like that 
in rabbit cerebral cortex. The Kd value of 0.6 nM is close to that obtained in the rabbit, 1.1 
nM. The Kd value determined by specific binding of [^H]8-OH-DPAT in the rat brain was 
0.8 nM, falling  just between the other two values. All three of these values fall within the 
range of previously reported Kd's (Beer, et al., 1990; Hoyer, et al., 1994), and suggest that a 
similar binding site is being labeled in the three species.
Displacement values for buspirone and propranolol gave another means of 
comparing the 5-HTia receptor across species. The Ki values obtained for propranolol were 
almost identical in the rabbit brain and for human receptor, 78 and 73 nM, respectively. The
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
53
Ki values for buspirone displacement showed more variation. Buspirone showed a higher 
affinity for the expressed human 5-HTia receptor with a Kj of 5.1 nM compared to 26 nM 
for rabbit brain and 37 nM for rat. The Ki value for rat lies outside of the range of previous 
reported values (Zifa and Pillion, 1992).
The Ki value of 5.1 nM reported here for the buspirone displacement at human 
receptor is almost identical to the value of 4.0 nM reported by Fargin et al. (1988) for the 
human clone. Although the transfected human receptor expressed in CHO cells appears to 
be biochemically similar to the receptor in other species, one cannot forget the fact that the 
receptor is no longer in its native physiological environment. This may account for the 
higher affinity that buspirone displayed for this receptor in comparison to rabbit and rat. 
Certainly, the fact that this receptor is not in its normal environment should always be 
accounted for.
Another possible explanation for the differing values could be due to the 
anesthetization of the animals. Although pentobarbital does interact with 5-HT receptors, it 
is with low affinity, and it is estimated that this effect is minimal. The fact that the Kj values 
for the propranolol studies in rabbit and the human receptor were almost identical tends to 
support the idea that pentobarbital is not having a significant affect on the binding data.
The buspirone K, values for both human 5-HTia receptor and that in rabbit brain are 
both within the range of previously reported values (Zifa and Pillion, 1992). The rat Ki 
value reported here is slightly higher than the previously reported highest value of 29.5 nM 
in rat hippocampus (Gozlan et al., 1983). Assay conditions used here were different from
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those used by Gozlan et al. (1983), and may account for the differences. The high amount of 
error with the buspirone displacement should also be taken into account, and may be partly 
responsible for the variations that are seen with the buspirone values.
Viewing previously reported data in the literature and the data presented here, the 
rabbit brain 5-HTia receptor seems to exhibit similar characteristics to those reported of the 
5-HTia receptor in other mammalian species. This receptor shows similar characteristics 
across different mammalian orders, Lagomorpha (rabbit), Rodentia (rat), and Primates 
(human). The rabbit has often been used as a model when investigating 5-HT receptors in 
the brain (Dewar, et al., 1990; Feuerstein, et al., 1987; Schoups, et al., 1986; Schoups and 
DePotter, 1988), yet the 5-HTia receptor was never fully characterized in this species. 
Based on these results, the pathology and physiology of this receptor can be confidently 
studied in the rabbit brain, and data obtained in this species should be applicable to human 
research.
SOLUBILIZED HUMAN 5-H T ia RECEPTOR
Because certain techniques that are used to investigate receptor-ligand interactions, 
such as multidimensional NMR, require a large amount of pure receptor, the receptor must 
be solubilized from its membrane locations. The preliminary experiments reported here 
were undertaken to investigate if solubilized human 5-HT i a receptor cultured in CHO cells
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maintains biochemical and pharmacological binding characteristics comparable to those of 
membrane anchored receptor.
Displacement studies using buspirone produced a Kj value of 4.3 nM for receptor 
solubilized with Na cholate, which is very close to the value of 5.1 nM exhibited in 
nonsolubilized human receptor. Receptor solubilized with CHAPS produced a lower 
affinity of buspirone for the receptor with a Kj value of 80 nM. Experiments using n-octyl- 
b-D-pyranoside (0.6%) as the solubilizing failed to show any displacement of [^H]8-OH- 
DPAT by buspirone. A GTP inhibition experiment was run using CHAPS as the 
solubilizing agent. GTP dose-dependently inhibited the binding of [^H]8-OH-DPAT to 
solubilized human 5-HTia receptor. An IC50 value of 0.1 uM was determined for the 
interaction.
Based on this preliminary data, the solubilized receptor seems to maintain its 
biochemical and binding characteristics after its removal from the membrane. Buspirone 
certainly had a higher affinity for receptor solubilized by Na cholate, but because of its 
compatibility with techniques like NMR , CHAPS was utilized in the GTP experiment. The 
result produced by this experiment suggests that the receptor is remaining G protein linked 
after solubilization. Certainly, many more experiments are needed, but these preliminary 
results suggest that the qualities of the 5-HT 1 a receptor expressed in a tissue culture system 
can be maintained after solubilization with detergents.
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PARTHENOLIDE
Parthenolide showed very low activity at the 5-H T ia receptor. A IQ value in excess 
o f 1.0 mM was obtained, in comparison to a drug with known high afHnity for this receptor, 
buspirone, which exhibited a IQ value of 26 nM. Parthenolide did not exhibit any affinity at 
the 5-H T id receptor, as it failed to displace [^H]5-CT from these binding sites. These results 
are not entirely suprising, as feverfew has generally been used in the prevention of migraine 
attacks (Awang, et al., 1991). Based on the hypothetical involvement of 5-HT receptors in 
migraine pharmacotherapy, an interaction at S-HTj receptors would seem to be more 
expected for a compound working as a prophylactic medicine for migraine.
The interaction of parthenolide at S-HTg receptors was investigated by comparing 
the displacement of [^H]ketanserin with compounds of known affinity for these binding 
sites, methysergide and mesulergine. Methysergide, a S-HTi antagonist that has been 
employed as an anti-migraine drug, exhibited a IQ of of 5.7 nM, and thus high affinity for 
the 5 -HT2 receptor in rabbit cerebral cortex. This value falls well within the range reported 
by other researchers for mammalian species, from 0.94 to 12 nM (Leysen, et al., 1982; Zifa 
and Pillion, 1992). It is exactly the 5.7 nM value that was reported by Peroutka (1990). High 
affinity binding to 5 HTz sites was also shown by mesulergine, which exhibited a IQ of 8.3 
nM. This value also correlates well with those reported of other researchers (Zifa and 
Pillion, 1992). Because of the non polar properties of parthenolide, it was necessary to first 
dissolve the chemical in absolute ethanol before further diluting in the assay buffer. A 
control experiment was run to investigate the potential interaction of ethanol with 5-HTi
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receptors. Ethanol was tested at the highest concentration in which appeared in the final 
assay volume (2.0%), and it alone failed to disrupt any binding of [^H]ketanserin. Therefore, 
assay conditions appear to be appropriate for the analysis of the interactions of parthenolide 
with these receptors. When mesulergine was used for non-specific binding, parthenolide 
produced an IC50 value of exactly l.QmM. When methysergide represented non-specific 
binding, a Ki of 234 nM was obtained. Therefore, parthenolide is displacing [^H]ketanserin 
from its binding sites, but with very low affinity, and certainly is not compatible with the 
high affinities that are displayed by the 5-HT2 antagonists, methysergide and mesulergine.
Experiments were also conducted using [^H]5-HT to examine if parthenolide was 
displacing serotonin from any high affinity sites and to determine if any other 5-HT 
receptors may possibly be involved in the action of this substance. No displacement of 
[^H]5-HT was exhibited. Based on these results, parthenolide does not appear to exhibit its 
reputed effects by acting directly at 5-HT receptors. A few conclusions can be made.
The proposed hypothesis to explain the efficacy of 5-HTz receptor antagonists in 
treating migraine is as follows. These receptors have been found to mediate contraction of 
smooth muscles in the vasculature (Peroutka, 1984), and it has also been shown that 5-HT 
can stimulate the production of prostacyclin and other arachidonic acid metabolites in 
smooth muscle (Coughlin, et al., 1981; Coughlin, et al, 1984). 5-HTz antagonists, like 
methysergide, have been demonstrated to block these effects. Therefore, they appear to be 
mediated through a S-HTa mechanism. Because 5-HTz receptors are positively linked to 
phospholipase C, and phospholipase C can stimulate arachidonic acid metabolism, this adds
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support to the hypothesis. The importance of these findings are that modulation of 
arachidonic acid metabolism may have important effects on vascular tone, and 5-HT could 
stimulate arachidonic acid metabolism at the beginning of a migraine attack, via 5 -HT2 
receptors. This could lead to an inflammatory reaction in the brain vasculature, and 
theoretically, S-HTz antagonists are able to inhibit 5-HT from inducing this inflammatoiy 
state. Once this inflammatory reaction has begun however, 5-HT2 antagonists would be of 
little benefit (Peroutka, 1990a).
Parthenolide may work by a mechanism that is associated with this hypothesis. This 
compound has been shown to inhibit the release of 5-HT from blood platelets 
(Groenewegen and Hepinstall, 1990; Maries, et al., 1992). Perhaps, through this mechanism 
alone, it is inhibiting the induction of this inflammatory state by blocking 5-HT release, 
which would otherwise stimulate arachadonic acid metabolism. Importantly, extracts of 
feverfew have been shown to inhibit both 5-lipoxygenase and cyclo-oxygenase pathways of 
endogenous arachidonic acid metabolism (Sumner, et al., 1992). It may block an 
inflammatory reaction leading to a migraine attack by inhibiting these enzymes. Still, it may 
be a combination of this latter mechanism with the inhibition of 5-HT from platelets that 
produces the anti-migraine effects.
Another possibilty is that, due to the difficulties of getting parthenolide into 
solution, there may not be enough of the substance in the assay volume to show a significant 
amount of binding to receptors. Every effort was made to insure that parthenolide was 
indeed in solution. An experiment was also run in the presence of a solubilizing agent, but it
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failed to show any improvement of the displacing of [^HJketanserin by parthenolide. The 
possibilty that parthenolide was not fully in solution should not be completely ruled out.
Still, another possibility is that some other chemical in the plant or a combination of 
parthenolide and other chemicals, lead to the efficacy of feverfew. Sumner, et al. reported 
(1992) that parthenolide was a potent inhibitor of arachadonic acid metabolism, but they 
also found that extracts which did not contain parthenolide inhibited this metabolism as 
well. Therefore, the presence of parthenolide is not necessary for this effect. Other 
investigators have shown that dried and fresh leaves of feverfew have different 
pharmacological profiles on vascular smooth muscle (Barsby, et al., 1992). Dried leaves 
lack some of the effects that are seen in fresh leaves and therefore, it may be advantageous 
to ingest fresh feverfew leaves for maximum efficacy. These effects were attributed to 
sequiterpene lactone content, which includes parthenolide.
Therefore, questions arise as to whether or not parthenolide has potential alone as an 
anti-migraine agent, or if it is necessary to ingest the leaves of feverfew to produce desired 
effects, which have been verified in clinical trials (Johnson, et al., 1985; Murphy et al., 
1988). In light of these findings, an experiment was conducted in which crude extracts of 
parthenolide were investigated for their potential of displacing [^H]ketanserin binding. 
Crude extracts that were reconstituted in pure ethanol did not displace [^H]ketanserin 
binding. However, a liquid extract of 95% ethanol displaced [^H]ketanserin binding by 
approximately 50%. This result suggests that some polar component of the plant may be 
binding to 5 -HT2 receptors, or that a combination of chemicals is producing a displacement
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of [^H]ketanserin binding. This finding is very preliminary and crude at best, but it does 
suggest that further experiments investigating the potential interaction of the products of 
feverfew with 5-HT receptors, are warranted.
CONCLUSIONS:
A. The 5-HTia binding site in the rabbit brain exhibits similar characteristics to those found 
of 5-HT: A receptors in other mammalian species. The 5-HTia site in rabbit brain appears to 
be G protein-linked, a characteristic found of the 5-HTia receptor in other species. The 
rabbit 5-HTia site also exhibits similar binding characteristics in comparison to rat and 
human 5-HTia receptor. Therefore, the physiology and pathology that is associated with the 
5-HTiA receptor can be studied confidently in the rabbit brain.
B In preliminary studies, human 5-HTia receptor that is expressed in CHO cells appears to 
maintain the qualities of membrane-bound receptor after solubilization with detergents.
C. The potential anti-migraine substance, parthenolide, does not appear to interact with 5- 
HTja or 5-HTid receptors. Parthenolide does bind to 5 -HT2 receptors, but with low 
affinity. Therefore, parthenolide does not appear to produce its hypothesized anti-migraine 
effects by binding directly to 5-HT receptors in the brain. Parthenolide may produce anti-
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
61
migraine effects through another mechanism. Another possibility is that some other 
chemical in the feverfew plant is responsible for these effects, or that parthenolide in 
combination with other constituents in the plant are responsible for its effects.
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